SANOFI-ADR (SNY)
US80105N1054 - ADR
SANOFI-ADR
NASDAQ:SNY (12/20/2024, 8:00:02 PM)
After market: 47.71 0 (0%)47.71
+0.21 (+0.44%)
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 87,994 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008
P: 33153774000
CEO: Paul Hudson
Employees: 86088
Website: https://www.sanofi.com/
SNY News
a day ago - The Motley FoolWhy Cytokinetics Stock Was a Nearly 5% Winner Today
2 days ago - ChartmillIn a market where value is scarce, NASDAQ:SNY offers a refreshing opportunity with its solid fundamentals.When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
5 days ago - Investor's Business DailyTeva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied DrugTeva and Sanofi are partnered on a drug to treat inflammatory bowel disease. The drug showed "best-in-class potential" in midstage testing.
5 days ago - Yahoo FinanceWhy Are Teva And Sanofi Stocks Trading Higher On Tuesday?On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug
6 days ago - ChartmillWhy NASDAQ:SNY qualifies as a good dividend investing stock.Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY).
17 days ago - The Motley Fool2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian InvestorsSNY Twits
Here you can normally see the latest stock twits on SNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
